Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a pioneering biotechnology firm headquartered in the United States, is at the forefront of developing innovative cancer therapies. Founded in 2018, the company focuses on harnessing the power of monoclonal antibodies and other advanced technologies to create targeted treatments for various malignancies. With a commitment to addressing unmet medical needs, Pyxis Oncology has made significant strides in its research and development efforts, particularly in the realm of immuno-oncology. The company’s unique approach to drug development sets it apart in a competitive market, positioning it as a notable player in the oncology sector. As it continues to advance its pipeline of promising therapies, Pyxis Oncology remains dedicated to improving patient outcomes and redefining cancer treatment paradigms.
DitchCarbon Score
How does Pyxis Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pyxis Oncology, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pyxis Oncology, Inc.'s reported carbon emissions
Pyxis Oncology, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As such, Pyxis Oncology does not appear to have established any significant commitments towards reducing its carbon footprint or addressing climate change at this time. In the context of the biotechnology industry, many companies are increasingly focusing on sustainability and setting ambitious targets to reduce greenhouse gas emissions. However, without specific data or commitments from Pyxis Oncology, it remains unclear how the company aligns with these industry trends.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pyxis Oncology, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
